Special Issue

Overcoming Drug Resistance to Systemic Therapy in Breast Cancer

Message from the Guest Editors

Breast cancer is the second most common malignancy in women worldwide. The cause of cancer is multifactorial. The early diagnosis and appropriate treatment of cancer can improve the chances of survival. Other methods of early detection include selfexamination, clinical breast examination, and imaging tests such as ultrasound and MRI. Breast cancer is a heterogeneous disease that is considered complex, as there is great diversity within tumors. Despite extensive research, the exact etiology of the disease has not yet been elucidated, as the identified genetic and epigenetic interactions cannot explain the cause of breast cancer in most cases. This Special Issue will explore the current state of research in the field of drug resistance, including the mechanisms of drug resistance, the development of new drugs and immunotherapies, and the potential for combination therapies. It will also discuss the challenges associated with drug resistance and the strategies that can be used to address them. Finally, the Special Issue will consider the implications of drug resistance for public health and the need for new approaches to combat this growing problem.

Guest Editors

Dr. Nethaji Muniraj

Children's National Hospital, Center for Cancer and Immunology Research, Washington, DC, USA

Dr. Dimiter B. Avtanski

Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY 10022, USA

Deadline for manuscript submissions

closed (15 October 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/168200

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

